Clinical Trial Update: Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating extended-release niacin for atherosclerosis in saphenous vein grafts used in coronary bypass; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Bypass Graft Atherosclerosis
• Saphenous Vein Graft Atherosclerosis

Drugs mentioned

• Extended-release Niacin (Niacin (extended-release))

Snippet

Sponsor: North Texas Veterans Healthcare System | Conditions: Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis, Intermediate Saphenous Vein Graft Lesions | Phase 2 | Status: COMPLETED